AbCellera Biologics (ABCL) Competitors $2.00 +0.01 (+0.50%) Closing price 04:00 PM EasternExtended Trading$2.02 +0.02 (+1.00%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ABCL vs. HCM, AMRX, OGN, MIRM, APLS, DNLI, VCEL, AAPG, NAMS, and KYMRShould you be buying AbCellera Biologics stock or one of its competitors? The main competitors of AbCellera Biologics include HUTCHMED (HCM), Amneal Pharmaceuticals (AMRX), Organon & Co. (OGN), Mirum Pharmaceuticals (MIRM), Apellis Pharmaceuticals (APLS), Denali Therapeutics (DNLI), Vericel (VCEL), Ascentage Pharma Group International (AAPG), NewAmsterdam Pharma (NAMS), and Kymera Therapeutics (KYMR). These companies are all part of the "pharmaceutical products" industry. AbCellera Biologics vs. HUTCHMED Amneal Pharmaceuticals Organon & Co. Mirum Pharmaceuticals Apellis Pharmaceuticals Denali Therapeutics Vericel Ascentage Pharma Group International NewAmsterdam Pharma Kymera Therapeutics HUTCHMED (NASDAQ:HCM) and AbCellera Biologics (NASDAQ:ABCL) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, community ranking, risk, analyst recommendations and valuation. Is HCM or ABCL more profitable? HUTCHMED has a net margin of 0.00% compared to AbCellera Biologics' net margin of -533.32%. HUTCHMED's return on equity of 0.00% beat AbCellera Biologics' return on equity.Company Net Margins Return on Equity Return on Assets HUTCHMEDN/A N/A N/A AbCellera Biologics -533.32%-15.73%-12.22% Does the media favor HCM or ABCL? In the previous week, AbCellera Biologics had 7 more articles in the media than HUTCHMED. MarketBeat recorded 8 mentions for AbCellera Biologics and 1 mentions for HUTCHMED. AbCellera Biologics' average media sentiment score of 0.56 beat HUTCHMED's score of 0.28 indicating that AbCellera Biologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HUTCHMED 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AbCellera Biologics 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community favor HCM or ABCL? HUTCHMED received 260 more outperform votes than AbCellera Biologics when rated by MarketBeat users. However, 76.00% of users gave AbCellera Biologics an outperform vote while only 66.18% of users gave HUTCHMED an outperform vote. CompanyUnderperformOutperformHUTCHMEDOutperform Votes31766.18% Underperform Votes16233.82% AbCellera BiologicsOutperform Votes5776.00% Underperform Votes1824.00% Which has better earnings and valuation, HCM or ABCL? HUTCHMED has higher revenue and earnings than AbCellera Biologics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHUTCHMED$630.20M3.67$100.78MN/AN/AAbCellera Biologics$23.11M25.82-$146.40M-$0.56-3.57 Do institutionals and insiders believe in HCM or ABCL? 8.8% of HUTCHMED shares are owned by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are owned by institutional investors. 3.6% of HUTCHMED shares are owned by company insiders. Comparatively, 28.9% of AbCellera Biologics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Do analysts rate HCM or ABCL? HUTCHMED presently has a consensus target price of $19.00, indicating a potential upside of 43.18%. AbCellera Biologics has a consensus target price of $8.33, indicating a potential upside of 316.67%. Given AbCellera Biologics' stronger consensus rating and higher possible upside, analysts plainly believe AbCellera Biologics is more favorable than HUTCHMED.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HUTCHMED 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00AbCellera Biologics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Which has more risk and volatility, HCM or ABCL? HUTCHMED has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500. Comparatively, AbCellera Biologics has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500. SummaryAbCellera Biologics beats HUTCHMED on 9 of the 16 factors compared between the two stocks. Get AbCellera Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for ABCL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABCL vs. The Competition Export to ExcelMetricAbCellera BiologicsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$596.85M$6.49B$5.33B$8.39BDividend YieldN/A2.64%5.21%4.11%P/E Ratio-3.289.1826.8919.71Price / Sales25.82252.26386.75120.59Price / CashN/A65.8538.2534.62Price / Book0.506.456.774.50Net Income-$146.40M$144.21M$3.23B$248.22M7 Day Performance-0.99%2.46%1.82%0.56%1 Month Performance-20.63%4.59%11.12%13.17%1 Year Performance-48.19%-2.68%17.09%7.30% AbCellera Biologics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABCLAbCellera Biologics2.7477 of 5 stars$2.00+0.5%$8.33+316.7%-48.3%$596.85M$23.11M-3.28500Gap UpHCMHUTCHMED2.237 of 5 stars$13.92-2.0%$19.00+36.5%-33.6%$2.43B$630.20M0.001,760News CoveragePositive NewsAnalyst DowngradeGap DownAMRXAmneal Pharmaceuticals3.27 of 5 stars$7.60+2.6%$11.50+51.3%+8.7%$2.36B$2.83B-11.187,600Positive NewsOGNOrganon & Co.4.7484 of 5 stars$8.69+0.0%$18.00+107.1%-61.3%$2.26B$6.29B2.6110,000High Trading VolumeMIRMMirum Pharmaceuticals4.0842 of 5 stars$45.57+2.9%$59.00+29.5%+71.8%$2.25B$379.25M-22.56140News CoveragePositive NewsAnalyst ForecastAnalyst RevisionAPLSApellis Pharmaceuticals4.2031 of 5 stars$17.52+1.2%$41.37+136.2%-59.1%$2.20B$781.37M-8.63770Positive NewsAnalyst ForecastDNLIDenali Therapeutics4.4978 of 5 stars$14.80+3.0%$33.79+128.3%-31.5%$2.15B$330.53M-5.36430Analyst ForecastGap UpVCELVericel2.6898 of 5 stars$42.67+2.3%$60.86+42.6%-20.3%$2.14B$238.54M711.29300News CoveragePositive NewsAnalyst ForecastAAPGAscentage Pharma Group InternationalN/A$24.29-0.1%N/AN/A$2.11B$980.65M0.00600Positive NewsGap DownNAMSNewAmsterdam Pharma2.6839 of 5 stars$19.16+4.3%$43.00+124.4%-5.0%$2.10B$45.56M-10.194Analyst DowngradeGap UpKYMRKymera Therapeutics2.7503 of 5 stars$32.17+7.0%$55.53+72.6%-14.7%$2.09B$47.07M-13.75170Positive NewsAnalyst Forecast Related Companies and Tools Related Companies HUTCHMED Competitors Amneal Pharmaceuticals Competitors Organon & Co. Competitors Mirum Pharmaceuticals Competitors Apellis Pharmaceuticals Competitors Denali Therapeutics Competitors Vericel Competitors Ascentage Pharma Group International Competitors NewAmsterdam Pharma Competitors Kymera Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ABCL) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AbCellera Biologics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AbCellera Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ABCL Stock Free ABCL Stock Alerts